ArticleEuropean journal of clinical pharmacology2026
Secondary data analysis of Adverse Drug Reactions reported by healthcare professionals and patients: interventions to manage ADRs of ACE inhibitors and ARBs.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrescribing cascades occur when an adverse drug reaction (ADR) of a first medication is treated with a second medication, potentially leading to polypharmacy and harm. While various interventions are recommended to prevent harm, it is unknown which are implemented in daily practice. This study aims to assess the interventions implemented for ADRs of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB).
methodsThis cross-sectional study analysed secondary data from spontaneous ADR reports submitted to the Netherlands Pharmacovigilance Center Lareb. Reports were included if the ADR was suspected to be caused by an ACE inhibitor or ARB and an intervention was documented. The primary outcome was the proportion of ADRs treated with (1) dose reduction, (2) discontinuation of the suspected medication, (3) discontinuation followed by medication to treat the ADR, (4) switching to alternative medication, or (5) addition of marker medication (prescribing cascade). The secondary outcome was the proportion of ADRs resolved at the time of the ADR report.
resultsA total of 902 ADR reports were included. The most frequent intervention was discontinuing the suspected medication, followed by introducing medication to treat the ADR (42.5%), resulting in a large proportion of resolved ADRs (46.5%). However, 11.9% of reports included prescribing cascades, resolving the ADR in only 25.2% of reports.
conclusionUsing real-world pharmacovigilance data, this study offers valuable insights into the treatment of ADRs of ACE inhibitors and ARBs in daily practice. Further research is needed to establish the most effective interventions for specific types of ADRs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.